Stock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects

Stock Track

Nov 06, 2024

Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.

The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.

Adding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1155669705"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155669705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155669705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155669705","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.</p>\n\n<p>The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.</p>\n\n<p>Adding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-06 16:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.</p>\n\n<p>The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.</p>\n\n<p>Adding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1155669705","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155669705","pubTimestamp":1730881727,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.Adding","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票赛道Hims&Hers因强劲的第三季度业绩和增长前景而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.\nThe company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.\nAdding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}